PUBLISHER: DataM Intelligence | PRODUCT CODE: 1304535
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1304535
Global Polycystic Ovary Syndrome Market - 2023-2030
Market Overview
The Global Polycystic Ovary Syndrome Market reached US$ 3.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 4.6 billion by 2030. The Global Polycystic Ovary Syndrome Market is expected to exhibit a CAGR of 5.5% during the forecast period 2023-2030.
The increasing cases of polycystic ovary syndrome, increase in the prevalence of risk factors, growing awareness, funding initiatives, increasing search activities, favorable reimbursement policies, and market developments such as product launches, product authorizations, alliances, acquisitions, coalitions, and expansion among others are expected to boost the Global Polycystic Ovary Syndrome Market growth in the forecast period. The key market players in this market include Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, Novartis, and Takeda Pharmaceutical Company Limited, among others.
Market Dynamics
Increasing Cases of Polycystic Ovary Syndrome Drive The Growth Of The Polycystic Ovary Syndrome Market.
Polycystic ovarian syndrome (PCOS) is a typical endocrine/hormonal condition that impacts females, primarily after puberty. Alternatively, PCOS might be developed as polycystic ovary syndrome. About 5-15% of females in the reproductive age class encounter hormonal inequalities that direct to menstrual abnormalities, cysts in ovaries, infertility, and additional health issues involving cardiovascular difficulties, type 2 diabetes mellitus (T2DM), and endometrial cancer.
The World Health Organization (WHO) data indicates that roughly 116 million females (3.4%) are impacted by PCOS worldwide. Moreover, according to the PCOS Awareness Association, PCOS affects more than 7 million females in the US, which is high than the number of females diagnosed with breast cancer, rheumatoid arthritis, multiple sclerosis, and lupus combined.
The increasing research funding is Expected To Present The Global Polycystic Ovary Syndrome Market With Growth Opportunities.
The increasing research funding is presenting the global market with lucrative growth opportunities in the future. For instance, in the latest five financial years to 2019-2020, the NIHR and UKRI have granted £8.52m for an investigation into endometriosis and £6.60m for an inquiry into polycystic ovary syndrome. This encloses a broad scope of tasks from fundamental science to applied health investigation into diagnosis, therapy, and assistance delivery.
Side Effects of Treatment are Estimated To Hamper The Global Polycystic Ovary Syndrome Market During The Forecast Period.
The side effects caused by the polycystic ovary syndrome treatment hamper the global market growth during the forecast period. For instance, the polycystic ovary syndrome treatment includes hypoglycemic agents, which can lead to gastrointestinal upset, lactic acidosis, increase in homocysteine levels, weight gain, congestive heart failure, and edema, among other side effects associated with different treatment options.
COVID-19 Impact Analysis.
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations worldwide. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
Russia-Ukraine War Impact Analysis.
The Russia-Ukraine brawl is considered to carry minimal impact on the global polycystic ovary syndrome market as the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids.
There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of basic materials are predicted to have a small influence on the global Polycystic Ovary Syndrome market growth in the forecast period.
Segment Analysis
The Global Polycystic Ovary Syndrome Market is segmented based on treatment type, end-user, and region.
Owing To The Increasing Research Investments Surgical Treatment Segment Is Estimated To Hold About 34.1% Of The Global Market Share By 2030.
Owing to the benefits of surgical treatment in patients not responding to drug treatment, surgical treatment is estimated to hold 34.1% of the global market share by 2030. For instance, according to the NHS, a nominal surgical process called laparoscopic ovarian drilling (LOD) might be a therapy choice for fertility issues related to PCOS that do not react to the medicine.
Geographical Analysis
Europe is Estimated to Hold 26.3% of the Market Share Owing to the Growing Polycystic Ovary Syndrome Prevalence in this Region.
Owing to the increasing prevalence and active research projects the Europe region is estimated to hold the second-largest share of the global market, accounting for about 26.3% of the total market share by 2030. For instance, according to the NHS, it is challenging to understand precisely how many females have PCOS, though it is presumed to be highly typical, impacting around 1 out of 10 females in the UK. Over 50% of these females do not encounter any manifestations.
Moreover, the EU-funded SPIOMET4HEALTH project strives to estimate an innovative practice concentrating on the additive outcomes of SPIOMET's elements. The project desires to deliver the first large-scale proof of tried medicines' psychosocial advantages and contribute to responsible decision-making regarding PCOS across European healthcare systems.
Competitive Landscape
The major global players in the polycystic ovary syndrome market include: Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, Novartis, Takeda Pharmaceutical Company Limited, Abbvie, Ferring BV, Merck KGaA, EffRx, Inc., among others.
Why Purchase the Report?
- To visualize the Global Polycystic Ovary Syndrome Market segmentation based on treatment type, end-user, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous polycystic ovary syndrome market-level data points with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of critical products of all the major players.
The Global Polycystic Ovary Syndrome Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Treatment Type
- 3.2. Snippet by End-user
- 3.3. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing Market Developments
- 4.1.1.2. Growing Prevalence
- 4.1.2. Restraints
- 4.1.2.1. Side Effects
- 4.1.3. Opportunity
- 4.1.3.1. Increasing Research Fundings
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. By Treatment Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 7.1.2. Market Attractiveness Index, By Treatment Type
- 7.2. Drug Treatment *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Contraceptives
- 7.2.4. Insulin-sensitizing Agent
- 7.2.5. Antidepressants
- 7.2.6. Anti-obesity
- 7.2.7. Other Drug Classes
- 7.3. Surgical Treatment
- 7.3.1. Ovarian Wedge Resection
- 7.3.2. Laparoscopic Ovarian Drilling
- 7.3.3. Other Surgeries
8. By End-user
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 8.1.2. Market Attractiveness Index, By End-user
- 8.2. Hospitals *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Specialty Clinics
- 8.4. Others
9. By Region
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.2.5.1. The U.S.
- 9.2.5.2. Canada
- 9.2.5.3. Mexico
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.3.5.1. Germany
- 9.3.5.2. The U.K.
- 9.3.5.3. France
- 9.3.5.4. Spain
- 9.3.5.5. Italy
- 9.3.5.6. Rest of Europe
- 9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.4.5.1. Brazil
- 9.4.5.2. Argentina
- 9.4.5.3. Rest of South America
- 9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.5.5.1. China
- 9.5.5.2. India
- 9.5.5.3. Japan
Australia
- 9.5.5.4. Rest of Asia-Pacific
- 9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10. Competitive Landscape
- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
11. Company Profiles
- 11.1. Pfizer Inc *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
- 11.2. Bayer AG
- 11.3. Teva Pharmaceutical Industries Limited
- 11.4. Novartis
- 11.5. Takeda Pharmaceutical Company Limited
- 11.6. Abbvie
- 11.7. Ferring BV
- 11.8. Merck KGaA
- 11.9. EffRx, Inc
- 11.10. Bristol-Myer Squibb Company
LIST NOT EXHAUSTIVE
12. Appendix
- 12.1. About Us and Services
- 12.2. Contact Us
